Research ArticleOpen accessIn the keywordsStroke Prevention in Atrial Fibrillation: Pharmacologic UpdateWajeeha Saeed, J. W. Kusick, M. R. Sardar et al.For nearly half a century, the therapeutic options for the risk reduction of stroke in atrial fibrillation have been stagnant with vitamin K antagonists, such as warfarin, being the primary therapy. Although antiplatelet agents have been investigated over this time, they were never shown to reduce the risk of stroke at the level warfarin has. Considering the limited therapeutic options, … …Current Research in Medicine, Vol. 4, Issue 2 · 24 Jun 2013 · 6,762 accessesView PDFCite